About Ramya Ramaswami, M.B.B.S., M.R.C.P., M.P.H.

Ramya Ramaswami, M.B.B.S., M.R.C.P., M.P.H.

Ramya Ramaswami is a 2016-2017 NEJM editorial fellow. She is a medical oncologist within the National Health Services of the United Kingdom. Ramya received her medical degree, postgraduate medical and oncology training from Imperial College London, and a masters in public health from Columbia University, Mailman School of Public Health. Her clinical and research interests include cancer prevention, viral driven cancers, as well as disparities and access issues in global oncology.

All posts by Ramya Ramaswami, M.B.B.S., M.R.C.P., M.P.H.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

• November 2nd, 2016

Oncologists and patients with cancer eagerly await new therapies that efficiently target cancer and avoid damage to normal tissues. In 2015, a randomised controlled trial investigated the role of two immune checkpoint inhibitors: ipilimumab — an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody — and nivolumab — an anti-programmed death-1 (PD-1) antibody. Patients with untreated metastatic… Read More…


Romosozumab Treatment in Postmenopausal Women with Osteoporosis

• October 19th, 2016

You are seeing one of your patients, a vivacious and active 60-year-old woman who works full time. She underwent bone densitometry testing, and the results show a T score of -2.7 at the femoral neck. Further, a short sentence on the report confirms a diagnosis of osteoporosis. Knowing that osteoporosis can lead to both vertebral… Read More…


Adalimumab in Patients with Active Non-Infectious Uveitis

• September 8th, 2016

A 44-year-old woman with type 2 diabetes mellitus and sarcoidosis presents with a 3-week history of severe visual disturbance in both eyes. After referral to an ophthalmologist, she is diagnosed with idiopathic posterior uveitis. Her symptoms improved while receiving oral steroids over the course of 5 months. However, after completing steroid treatment, her glycemic control… Read More…


The 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer

• August 24th, 2016

“Your cancer has been successfully removed with surgery, but there may be a role for chemotherapy to protect you in the future.” This message is expressed by oncologists in consulting rooms all over the world. In women with early-stage breast cancer, adjuvant chemotherapy may be offered as an insurance policy against cancer recurrence. Risk of… Read More…


Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

• July 13th, 2016

Patients are fearful of nausea and vomiting during the course of cancer treatment, as it is an expected side effect of chemotherapy. Senior oncology physicians describe the early days of cancer treatment when large bowls lined the ward, positioned close to each patient. In the present age, we are still concerned about chemotherapy-induced nausea and… Read More…